22 Jul Emendo Biotherapeutics
Rachel Diamant, Chief Intellectual Property Officer and Head of Pipeline Development
Oct. 12 | 10:45am | BlueRock Therapeutics Ballroom
EmendoBio is a pioneering, next-generation CRISPR company. Our unique approach allows us to make any gene targetable, transforming the current landscape of genetic medicine. Founded and managed by a core group of graduates from the Weizmann Institute of Science, EmendoBio’s scientific team combines expertise in protein engineering, molecular biology, and gene editing systems. Our dual OMNI™ technology platforms enable us to perform precision gene editing while maintaining high efficiencies, allowing us to address disorders and diseases that were previously considered incurable.